Track: Disability, Life & CI

In this session, we will explore how two transformative treatment classes – microdosing psychedelics and GLP-1 receptor agonists – are poised to reshape the landscape of insurance claims, particularly in Life, Disability Income (DI), and Critical Illness (CI). Building on over 25 years of research, microdosing psychedelics is emerging as a promising alternative for mental health conditions like depression, anxiety and PTSD, offering neuroplastic benefits with fewer risks than traditional treatments. Since the approval of Prozac (fluoxetine) in 1987, antidepressant options have evolved, with psychedelics offering a groundbreaking shift in effectiveness and safety. Meanwhile, GLP-1 drugs are revolutionizing the treatment of metabolic conditions such as diabetes, obesity, and fatty liver with the potential to reduce excess mortality and reverse claims trends. From a medical director’s perspective, we’ll discuss how these innovations could improve patient outcomes and fundamentally alter the trajectory of insurance claims related to critical illness, disability, and premature death.